Clinical Trials Browser

Phase 2 × Disease × daratumumab × Clear all

NCT03896737 2025-08-11

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

Phase 2 Active not recruiting

Disease, Multiple Myeloma